Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

BPC-157

Body Protection Compound-157, PL-14736, Pentadecapeptide BPC 157

Quick Stats
Studies 196
Trials 1
Score 3
2022 pubmed 18 citations

Therapy Effect of the Stable Gastric Pentadecapeptide BPC 157 on Acute Pancreatitis as Vascular Failure-Induced Severe Peripheral and Central Syndrome in Rats.

Smoday. Ivan Maria IM; Petrovic. Igor I; Kalogjera. Luka L; Vranes. Hrvoje H; Zizek. Helena H; Krezic. Ivan I; Gojkovic. Slaven S; Skorak. Ivan I; Hriberski. Klaudija K; Brizic. Ivan I; Kubat. Milovan M; Strbe. Sanja S; Barisic. Ivan I; Sola. Marija M; Lovric. Eva E; Lozic. Marin M; Boban Blagaic. Alenka A; Skrtic. Anita A; Seiwerth. Sven S; Sikiric. Predrag P

Key Findings

  • BPC‑157 dramatically lowered pancreatic damage and blood amylase levels in rats with acute pancreatitis.
  • The peptide protected multiple organs (brain, heart, lungs, liver, kidneys) from injury caused by vascular blockage or high abdominal pressure.
  • It appears to work by activating collateral circulation, notably the azygos vein, restoring blood flow and preventing thrombosis.

Practical Outcomes

  • For biohackers, this study suggests BPC‑157 might have broad protective effects against severe vascular stress and pancreatitis, hinting at potential uses for gut and organ health. However, the data are from animal models only, so human dosing and safety remain uncertain. If experimenting, start with very low microgram‑per‑kg oral doses and monitor closely for any adverse effects.

Summary

In rats, giving the peptide BPC‑157 (tiny doses given by mouth or injection) helped prevent and heal severe pancreatitis and many other organ problems that happen when blood flow is blocked or damaged. The peptide seemed to open up backup blood vessels, especially the azygos vein, which reduced swelling, bleeding, and tissue death in the pancreas, brain, heart, lungs, liver, and kidneys.

Abstract

We revealed the therapy effect of the stable gastric pentadecapeptide BPC 157 (10 μg/kg, 10 ng/kg ig or po) with specific activation of the collateral rescuing pathways, the azygos vein, on bile duct ligation in particular, and acute pancreatitis as local disturbances (i.e., improved gross and microscopy presentation, decreased amylase level). Additionally, we revealed the therapy's effect on the acute pancreatitis as vascular failure and multiorgan failure, both peripherally and centrally following "occlusion-like" syndrome, major intoxication (alcohol, lithium), maintained severe intra-abdominal hypertension, and myocardial infarction, or occlusion syndrome, and major vessel occlusion. The application-sacrifice periods were ligation times of 0-30 min, 0-5 h, 0-24 h (cured periods, early regimen) and 4.30 h-5 h, 5 h-24 h (cured periods, delayed regimen). Otherwise, bile duct-ligated rats commonly presented intracranial (superior sagittal sinus), portal and caval hypertension and aortal hypotension, gross brain swelling, hemorrhage and lesions, heart dysfunction, lung lesions, liver and kidney failure, gastrointestinal lesions, and severe arterial and venous thrombosis, peripherally and centrally. Unless antagonized with the key effect of BPC 157 regimens, reversal of the inferior caval and superior mesenteric vein congestion and reversal of the failed azygos vein activated azygos vein-recruited direct delivery to rescue the inferior-superior caval vein pathway; these were all antecedent to acute pancreatitis major lesions (i.e., acinar, fat necrosis, hemorrhage). These lesions appeared in the later period, but were markedly attenuated/eliminated (i.e., hemorrhage) in BPC 157-treated rats. To summarize, while the innate vicious cycle may be peripheral (bile duct ligation), or central (rapidly developed brain disturbances), or peripheral and central, BPC 157 resolved acute pancreatitis and its adjacent syndrome.

Study Information

Provider

pubmed

Year

2022

Date

2022-06-01T00:00:00.000Z

DOI

10.3390/biomedicines10061299

Citations

18

References

86